BP1.4979 is a selective dopamine D3 receptor agonist which is under development for the treatment of binge-eating disorder, obsessive–compulsive disorder (OCD), restless legs syndrome (RLS), and smoking withdrawal. It is taken orally. The drug acts as a highly potent weak partial agonist of the dopamine D3 receptor (Ki = ~1 nM; EC50Tooltip half-maximal effective concentration = 0.7 nM; EmaxTooltip maximal efficacy = 32%). It has around 200-fold higher affinity for the dopamine D3 receptor than for the dopamine D2 receptor (Ki = 192 nM), where it is an antagonist. BP1.4979 showed 66% dopamine D3 receptor occupancy and 8% dopamine D2 receptor occupancy with positron emission tomography (PET) imaging in a clinical study. The time to peak levels of BP1.4979 is 1 hour and its elimination half-life is about 8 hours. The drug is under development by Bioprojet. As of January 2026, it is in phase 2 clinical trials for all indications.